Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Sabadell, Barcelona Clinical Trials

A listing of Sabadell, Barcelona clinical trials actively recruiting patients volunteers.

RESULTS

Found (104) clinical trials

This is a randomized, double-blind, placebo-controlled, multicenter phase III study. The study population will consist of approximately 1300 subjects with metastatic hormone sensitive prostate cancer (mHSPC), who will be randomized (1:1 ratio) to receive 600 mg (2 x 300 mg tablets) of darolutamide (ODM-201)/placebo twice daily with food, equivalent to ...

Phase

Impact of the Presurgical Visit of Nursing on the Well-being of the Surgical Patient.

In our Center, PNVs are carried out in the Ambulatory Area (External Consultations) in a specific and personalized nursing consultation, within an established and multidisciplinary program. One week before surgery, the patient and a family / primary caregiver are cited. The PNV conducts a semi-structured interview; the content may vary ...

Phase N/A

A Personalised Percutaneous External 3D Guide for Scaphoid Fixation

To carry out this analysis the investigators will recruit 10 patients who present with an acute fracture of the Scaphoid bone type B1 and B2 (Herbert Classification). A CT Scan will be performed and a 3D exoesqueleton model printed, previously deciding the position of the fixation screw inside of the ...

Phase N/A

A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

An interventional Phase 4 open-label, randomized, controlled, parallel-group, multi-country study in subjects with psoriatic arthritis (PsA) consisting of 2 parts: Part 1 is designed to compare the achievement of minimal disease activity (MDA) between subjects randomized to either adalimumab in combination with methotrexate (MTX) or MTX alone escalated to the ...

Phase

Phase III Radium 223 mCRPC-PEACE III

The objective of this randomized phase III open label trial is to assess if upfront combination of enzalutamide and Ra223 improves radiological progression-free survival compared to enzalutamide single agent in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone.

Phase

A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Na ve to Tumor Necrosis Factor (TNF) Inhibitors

This is a multicenter, Phase III, randomized, double-blind, double-dummy, parallel-group study to evaluate the safety, efficacy, and tolerability of etrolizumab compared with infliximab in treating participants with moderate to severe ulcerative colitis (UC) who are naive to tumor necrosis factor (TNF) inhibitors. Participants will be randomized in a 1:1 ratio ...

Phase

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

This is an event driven study to reach statistical power given all other assumptions. Subjects will visit the clinic 1 month after randomization and at regular intervals thereafter. Additionally, for any subject prematurely discontinuing study medication, assessments will be conducted every 6 months for the collection of study endpoints. Those ...

Phase

Adalimumab Intralesional in Intestinal Strictures of Crohn's Disease Patients

We study if the administration of intralesional Adalimumab (directly injected in the stricture) associated to endoscopic dilatation has a higher success rate at week 8 compared with placebo in patients with Crohn's disease who had confirmed intestinal stenosis (3 stenosis as maximum)

Phase

Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE

Induction Chemotherapy Vincristine (VCR): 1.5 mg/m2 (maximum dose 2 mg) iv days 1, 8, 15 and 22 daunorubicin (DNR) 45 mg/m2 i.v. days 1, 8, 15 and 22 Prednisone (PDN): 60 mg/m2 per day, i.v. or p.o., days 1-27 Imatinib 600 mg p.o. from day 1 until the beginning of ...

Phase

PRORADIUM: Prospective Multi-centre Study of Prognostic Factors in CRPC Patients Treated With Radium-223.

This is a non-interventional prospective study in metastatic CRPC designed to explore biomarkers, composed by patients treated with Radium-223. Key inclusion criteria: a) histological confirmation of prostate cancer; b) documented criteria (PCWG2) for CRPC; c) availability of tumour tissue; d) candidate for standard treatment with Radium-223. Primary end point: to ...

Phase N/A